HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,235.00
-45.00 (-1.37%)
Oct 10, 2025, 3:30 PM KST
-1.37%
Market Cap394.18B
Revenue (ttm)108.93B
Net Income (ttm)-77.70B
Shares Out121.85M
EPS (ttm)-654.16
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume435,005
Average Volume334,595
Open3,280.00
Previous Close3,280.00
Day's Range3,105.00 - 3,280.00
52-Week Range3,182.00 - 11,940.00
Beta-0.23
RSI29.25
Earnings DateNov 13, 2025

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 153
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.